Table 2 Characteristics of the patients with pseudoprogression after two cycles of ICIs according to EORTC
Patient number | Age (gender) | Therapy | 18F-FDG PET/CT findings | Interval between pseudoprogression and remission (months) | Death | OS (months) | Method for potential identification of pseudoprogression |
|---|---|---|---|---|---|---|---|
1 | 50 (M) | Ipilimumab/ nivolumab | Generalized lymphadenopathy | 2.3 | Yes | 26.9 | – |
2 | 55 (M) | Ipilimumab | Two newly emerging cervical lesions (one cutaneous and one subcutaneous) | 1.4 | No | 84.4 | Application of PERCIMT |
3 | 67 (M) | Ipilimumab | Increase in 18F-FDG activity and volume in existing tumor lesions | 6.0 | No | 66.7 | Application of PERCIMT |
4 | 61 (F) | Ipilimumab | Sarcoid-like lymphadenopathy, pneumonitis, thyroiditis | 1.4 | Yes | 43.5 | Identification of irAEs |
5 | 61 (M) | Ipilimumab | Increase in 18F-FDG activity, volume and number of tumor lesions | 2.3 | No | 96.1 | – |